Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
| Property | Thymosin Alpha-1 | KPV |
|---|---|---|
| Class | Peptide immunomodulator | Anti-inflammatory tripeptide |
| Research category | immunology and infectious disease | intestinal and skin inflammation models |
| Evidence level | Moderate | Low |
| Overall status | Approved in several countries (not in the US or EU) | Not approved — research |
| FDA | Not approved | Not approved |
| EMA | Not approved (national registrations vary) | Not approved |
| WADA | Check current list | Check current list |
| Mechanism studied | Thymosin α1 → Dendritic cells (TLR) → T-cell maturation → Immune response | KPV → PepT1 uptake → NF-κB inhibition → Inflammatory cytokines ↓ |
| Molecular weight | 3,108.3 g/mol | 192.21 g/mol |
| Sizes in stock | 5mg, 10mg | 10mg |
Where the research overlaps
These compounds sit in different research areas, which is often why researchers compare them directly. Thymosin Alpha-1 is classed as peptide immunomodulator, while KPV is anti-inflammatory tripeptide. Evidence is rated moderate for Thymosin Alpha-1 and low for KPV.
For a full write-up, read Thymosin Alpha-1 and KPV: Immune Peptide Research.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.